Peer-reviewed veterinary case report
Chemotherapy options and survival for dogs with high-grade T-cell
By Elliott, J & Baines, S·Published in Australian Veterinary Journal·2019·Willows Veterinary Centre & Referral Service, Highlands Road Solihull B90 4NH United Kingdom, United Kingdom·View original on Crossref →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: A Retrospective Study of Multi‐agent Chemotherapy including either Cyclophosphamide or Lomustine as Initial Therapy for Canine High‐grade T‐cell Lymphoma (2011‐2017)
- Species:
- dog
Plain-English summary
A group of dogs with high-grade T-cell lymphoma (a type of cancer) received chemotherapy as their first treatment. They were given either a combination of drugs that included cyclophosphamide or one that included lomustine. Both treatments worked, but dogs that received lomustine had a longer time without the cancer worsening and lived longer overall compared to those treated with cyclophosphamide. While some dogs experienced side effects like elevated liver enzymes and low white blood cell counts, the results suggest that lomustine may be a better option for treating this type of lymphoma in dogs.
People also search for: dog lymphoma treatment options · canine chemotherapy side effects · lomustine for dog cancer
Abstract
Multi‐agent chemotherapy (vincristine, epirubicin and prednisolone) including either cyclophosphamide (CEOP) or lomustine (LEOP) was given as first‐line chemotherapy to treatment‐naïve canine lymphoma patients with measurable, high grade T‐cell lymphoma (HGTCL). All patients responded to either CEOP or LEOP. Toxicity was typical of multi‐agent chemotherapy protocols and 25% of dogs receiving lomustine exhibited mild‐to‐moderate ALT elevation and 29% grade 3 or 4 neutropenia. Median progression‐free survival (100 versus 269 days) and overall survival (155 versus 327 days) were significantly higher in patients receiving LEOP compared to CEOP. Overall survival was improved for patients receiving LEOP compared to those receiving CEOP followed by lomustine‐based rescue therapy. The results of this retrospective study support further evaluation of lomustine as part of first‐line, multi‐agent therapy for patients with HGTCL.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Crossref: https://doi.org/10.1111/avj.12847